SCHEMBL5115355

SCHEMBL5115355

Cc1ccn2c(Nc3ccccc3)c(-c3ccc(C#Cc4ccccn4)s3)nc2c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 18/20 0.61
SMN1; SMN2 Q16637 11/20 0.61
KMT2A Q03164 4/20 0.61
HTT P42858 4/20 0.61
NPSR1 Q6W5P4 3/20 0.61
TDP1 Q9NUW8 3/20 0.61
MITF O75030 1/20 0.61
MAPT P10636 13/20 0.55
POLB P06746 4/20 0.55
TP53 P04637 7/20 0.52
THRB P10828 1/20 0.48
PKM P14618 1/20 0.47
PKLR P30613 1/20 0.47
LMNA P02545 3/20 0.46
MEN1 O00255 1/20 0.46
USP2 O75604 1/20 0.46
PPP1CA P62136 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
PTGS2 P35354 1/20 0.43
ALDH1A1 P00352 3/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5119098 0.88 GAA (0.46) GAASMN1; SMN2KMT2AHTTNPSR1
SCHEMBL5121465 0.86 GAA (0.55) GAASMN1; SMN2KMT2AHTTNPSR1
SCHEMBL5127401 0.83 GAA (0.45) GAASMN1; SMN2KMT2AHTTNPSR1
SCHEMBL5115347 0.83 GAA (0.62) GAASMN1; SMN2KMT2AHTTNPSR1
SCHEMBL5127205 0.77 GAA (0.43) GAASMN1; SMN2KMT2AHTTNPSR1
SCHEMBL5117468 0.75 GAA (0.39) GAASMN1; SMN2KMT2AHTTMAPT
SCHEMBL5127334 0.75 GAA (0.60) GAASMN1; SMN2KMT2AHTTNPSR1
SCHEMBL5118071 0.75 ADRA1B (0.51) GAASMN1; SMN2KMT2AHTTNPSR1
Hydrochloric Acid SCHEMBL5116906 0.74 ADRA1B (0.50) GAASMN1; SMN2KMT2AHTTNPSR1
Hydrochloric Acid SCHEMBL5127777 0.74 ADRA1B (0.50) GAASMN1; SMN2KMT2AHTTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1791840-B1 SUBSTITUTED BICYCLIC IMIDAZO-3-YLAMINE COMPOUNDS GRUENENTHAL GMBH (DE) 2013-11-27 EP claimed
US-7420056-B2 Substituted bicyclic imidazo-3-ylamine compounds GRUENENTHAL GMBH (DE) 2008-09-02 US claimed
US-20070155965-A1 SUBSTITUTED BICYCLIC IMIDAZO-3-YLAMINE COMPOUNDS GRUENENTHAL GMBH. (DE) 2007-07-05 US claimed
US-7420056-B2 Substituted bicyclic imidazo-3-ylamine compounds GRUENENTHAL GMBH (DE) 2008-09-02 US disclosed
US-20070155965-A1 SUBSTITUTED BICYCLIC IMIDAZO-3-YLAMINE COMPOUNDS GRUENENTHAL GMBH. (DE) 2007-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070155965-A1 SUBSTITUTED BICYCLIC IMIDAZO-3-YLAMINE COMPOUNDS AADAC, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PAICS GAA 234/4885SMN1; SMN2 1463/4885KMT2A 1107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.